LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that its molecular chaperone amplifying drug candidate iroxanadine has been shown to be effective in protecting against diabetic peripheral neuropathy (DPN) in animals. DPN is one of the earliest complications of diabetes and damages the nerves in arms, legs, hands and feet, resulting in a loss of normal sensory function, which then results in numbness, tingling, or pain. Since nerves are also necessary to sense the need for and then control local blood flow, DPN is considered to be a primary factor leading to the generation and persistence of intractable diabetic foot ulcers.
